Qualigen Therapeutics Stock Performance
| QLGN Stock | USD 4.47 0.31 6.49% |
The company holds a Beta of 0.76, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Qualigen Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Qualigen Therapeutics is expected to be smaller as well. At this point, Qualigen Therapeutics has a negative expected return of -0.87%. Please make sure to check Qualigen Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Qualigen Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Qualigen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (0.22) | Five Day Return 0.22 | Year To Date Return (83.90) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:50 | Dividend Date 2020-05-26 | Last Split Date 2024-11-05 |
1 | Qualigen Therapeutics, Inc. Announces Pricing of 3.46 Million Public Offering | 09/05/2024 |
2 | Univest Securities, LLC Announces Closing of 3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. | 09/06/2024 |
3 | Acquisition by Kruger Kurt H of 40000 shares of Qualigen Therapeutics subject to Rule 16b-3 | 09/18/2024 |
4 | Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel | 09/20/2024 |
5 | Insider Trading | 10/08/2024 |
6 | Acquisition by Shishir Sinha of 100000 shares of Qualigen Therapeutics subject to Rule 16b-3 | 10/18/2024 |
7 | Shares Expected to Begin Trading on Split-Adjusted Basis onNovember 5, 2024 | 11/01/2024 |
8 | Qualigen Therapeutics Announces 4.5 Million Private Placement of Convertible Preferred Shares | 11/19/2024 |
9 | Univest Securities, LLC Announces Successful Closing of 5. ... | 11/25/2024 |
| Begin Period Cash Flow | 7 M |
Qualigen |
Qualigen Therapeutics Relative Risk vs. Return Landscape
If you would invest 925.00 in Qualigen Therapeutics on August 29, 2024 and sell it today you would lose (478.00) from holding Qualigen Therapeutics or give up 51.68% of portfolio value over 90 days. Qualigen Therapeutics is currently does not generate positive expected returns and assumes 6.8029% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Qualigen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Qualigen Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Qualigen Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Qualigen Therapeutics, and traders can use it to determine the average amount a Qualigen Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1272
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | QLGN |
Estimated Market Risk
| 6.8 actual daily | 60 60% of assets are less volatile |
Expected Return
| -0.87 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Qualigen Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Qualigen Therapeutics by adding Qualigen Therapeutics to a well-diversified portfolio.
Qualigen Therapeutics Fundamentals Growth
Qualigen Stock prices reflect investors' perceptions of the future prospects and financial health of Qualigen Therapeutics, and Qualigen Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Qualigen Stock performance.
| Return On Equity | -8.42 | ||||
| Return On Asset | -0.75 | ||||
| Current Valuation | 4.34 M | ||||
| Shares Outstanding | 736.43 K | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 0.39 X | ||||
| Revenue | 5.2 M | ||||
| Gross Profit | 680.8 K | ||||
| EBITDA | (11.3 M) | ||||
| Net Income | (12.48 M) | ||||
| Cash And Equivalents | 6.62 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 2.13 X | ||||
| Book Value Per Share | (19.61) X | ||||
| Cash Flow From Operations | (10.3 M) | ||||
| Earnings Per Share | 3,635 X | ||||
| Market Capitalization | 3.29 M | ||||
| Total Asset | 2.03 M | ||||
| Retained Earnings | (116.8 M) | ||||
| Working Capital | (2.97 M) | ||||
About Qualigen Therapeutics Performance
By examining Qualigen Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Qualigen Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Qualigen Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 121.11 | 127.16 | |
| Return On Tangible Assets | (6.60) | (6.27) | |
| Return On Capital Employed | 5.37 | 5.64 | |
| Return On Assets | (6.60) | (6.27) | |
| Return On Equity | 6.38 | 6.70 |
Things to note about Qualigen Therapeutics performance evaluation
Checking the ongoing alerts about Qualigen Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Qualigen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Qualigen Therapeutics generated a negative expected return over the last 90 days | |
| Qualigen Therapeutics has high historical volatility and very poor performance | |
| Qualigen Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Qualigen Therapeuticshas 779,440 shares shorted by Qualigen Therapeutics investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 5.2 M. Net Loss for the year was (12.48 M) with profit before overhead, payroll, taxes, and interest of 680.8 K. | |
| Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| Latest headline from gurufocus.com: Univest Securities, LLC Announces Successful Closing of 5. ... |
- Analyzing Qualigen Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Qualigen Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Qualigen Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Qualigen Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Qualigen Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Qualigen Therapeutics' stock. These opinions can provide insight into Qualigen Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.6 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.